Internal Medicine, Infectious Disease · Sugar Land, TX
NPI
1972766327
Since 2008
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
4
Medicare group memberships
Hospitals
5
Hospital affiliations
6903 Brisbane Ct Ste 100
Sugar Land, TX, 77479
Phone (832) 886-4994
Groups this clinician bills Medicare through
Medicare paid, 2024
$722K
73,065 services
Medicare patients, 2024
1,199
Average age 74
Drug cost, 2024
$1.5M
2,751 prescriptions
Company payments, 2025
$23K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sarfraz Aly was code J1306 (injection, inclisiran, 1 mg), 9,656 times for 27 patients. In total Sarfraz Aly billed 73,065 services in 78 codes, and Medicare paid $722K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-05-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1306 Injection, inclisiran, 1 mg | Office | 9,656 | 27 | $9.49 | $92K |
| 99232 Hospital E&M - Subsequent | Facility | 4,405 | 821 | $56.23 | $248K |
| J0875 Injection, dalbavancin, 5 mg | Office | 4,125 | 11 | $11.25 | $46K |
| 99214 Office E&M - Established | Office | 697 | 296 | $87.84 | $61K |
| 99223 Hospital E&M - Initial | Facility | 556 | 482 | $123.41 | $69K |
| 99222 Hospital E&M - Initial | Facility | 339 | 307 | $93.57 | $32K |
| 96365 Intravenous Infusion, Hydration | Office | 248 | 29 | $46.45 | $12K |
| 99213 Office E&M - Established | Office | 240 | 39 | $68.60 | $16K |
| 99215 Office E&M - Established | Office | 201 | 110 | $125.70 | $25K |
| 99308 SNF E&M | Facility | 153 | 30 | $53.42 | $8,173 |
| 99239 Hospital Discharge Management | Facility | 125 | 104 | $81.84 | $10K |
| 99233 Hospital E&M - Subsequent | Facility | 114 | 85 | $84.12 | $9,589 |
| 99442 Telephone Services | Office | 83 | 52 | $62.55 | $5,191 |
| 99215 Office E&M - Established | Facility | 79 | 39 | $98.73 | $7,799 |
| 99204 Office E&M - New | Office | 79 | 79 | $119.05 | $9,405 |
By year: 2022 $659K for 15,543 services; 2023 $750K for 28,767 services; 2024 $722K for 73,065 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 35 | 27 | $2.20 | $77 |
Medicare prescription drug claims, 2024
In 2024, the drug Sarfraz Aly prescribed most often to Medicare patients was Ertapenem (Ertapenem Sodium), with 266 prescriptions and refills. In total Sarfraz Aly wrote 2,751 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ertapenem Ertapenem Sodium | 266 | 266 | 96 | $103K |
| Doxycycline Hyclate Generic | 215 | 255 | 122 | $3,672 |
| Ceftriaxone Ceftriaxone Sodium | 180 | 180 | 62 | $24K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 162 | 164 | 23 | $654K |
| Daptomycin Generic | 157 | 157 | 44 | $129K |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 110 | 116 | 72 | $1,574 |
| Ciprofloxacin Hcl Generic | 98 | 104 | 68 | $1,204 |
| Meropenem Generic | 95 | 95 | 34 | $14K |
| Fluconazole Generic | 85 | 85 | 52 | $928 |
| Levofloxacin Generic | 75 | 75 | 56 | $479 |
| Cefdinir Generic | 61 | 71 | 38 | $1,828 |
| Linezolid Generic | 56 | 56 | 43 | $8,352 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 54 | 74 | 30 | $373 |
| Fosfomycin Tromethamine Generic | 45 | 51 | 26 | $11K |
| Cefepime Hcl Generic | 35 | 35 | 12 | $5,547 |
Brand drugs: - claims; generic drugs: 2,357 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sarfraz Aly $23K ($23K in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbvie Inc. with $22K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 42 | $22K |
| MIMEDX Group, Inc. MDXG | 6 | $434 |
| Urgo Medical North America, LLC | 1 | $146 |
| Paratek Pharmaceuticals, Inc. | 4 | $92.98 |
| Gilead Sciences, Inc. GILD | 3 | $75.96 |
| Smith+Nephew, Inc. SNN | 1 | $62.52 |
| Kerecis Limited | 1 | $32.16 |
| La Jolla Pharmaceutical Company | 1 | $29.11 |
| Insmed, Inc. INSM | 1 | $28.84 |
| Merck Sharp & Dohme LLC MRK | 1 | $27.72 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.